Eli Lilly and Company

The three quality figures in the data point in different directions, and none of them is a verdict on the company. The Beneish M-Score is -1.846. That is below the -1.78 threshold, and its label is not in the elevated zone, meaning the screen did not flag the 2025 figures for manipulation risk. A screen like this cannot confirm or rule out problems, but it does not raise a flag here. Operating cash flow divided by net income is 0.81: Lilly generated $16.81 billion of operating cash flow against $20.64 billion of net income. A ratio below 1 means reported profit ran ahead of cash collected in 2025. That is the pattern a careful reader would check against working capital lines, including the rise in short-term income taxes payable and prepaid expenses noted in the 10-Q. Revenue growth of 44.7% is the scale signal, and the MD&A attributes it mainly to volume for Mounjaro and Zepbound. The Altman Z-double-prime score, Piotroski F-Score, and Fog Index are not on file in this data, so no values are given for them. On the business side, the filing ties future growth to a pipeline that includes orforglipron and to Ixo-vec, which came with the acquisition of Adverum Biotechnologies. It ties near-term pricing exposure to the IRA price selections and the November 2025 preliminary agreements. Readers may want to look at the 10-K risk factors on dependence on a relatively small number of products, and at the notes explaining acquired in-process research and development charges, which were $2.38 billion for the nine months ended September 30, 2025, compared with $3.09 billion a year earlier.

Catalyst.According to the MD&A, revenue reached $65.18 billion in 2025, up 44.7% from $45.04 billion, driven primarily by increased volume of Mounjaro and Zepbound, partially offset by lower realized prices. Net income rose to $20.64 billion from $10.59 billion, and diluted earnings per share were $22.95 versus $11.71. Management attributes the profit increase mainly to higher gross margin, partly offset by higher marketing, selling, and administrative expenses and research and development expenses. The pipeline section lists tirzepatide for heart failure with preserved ejection fraction as approved in the EU, and orforglipron for obesity as submitted in the U.S., the EU, and Japan, with a Commissioner's National Priority Voucher from the FDA.

Hidden risk.The MD&A says that in November 2025 Lilly announced preliminary voluntary agreements with the U.S. government, under which it agreed to lower Medicaid and certain other drug prices. Management warns it may fail to capitalize on expanded U.S. access to its obesity medicines if the added revenue is insufficient to offset those concessions. The Inflation Reduction Act has also selected Jardiance, effective 2026, and Trulicity and Verzenio, effective 2028. Separately, the September 30, 2025 10-Q balance sheet shows short-term income taxes payable of $9.44 billion, up from $1.12 billion at December 31, 2024, and prepaid expenses of $20.25 billion, up from $8.34 billion. The excerpt does not explain either change, so readers may want to look at the notes.